

## OncoZenge AB Nomination Committee Appointed

**STOCKHOLM, October 8, 2025.** In accordance with the resolution of the Annual General Meeting on May 28, 2025, the Chairman of the Board has contacted the company's three largest shareholders or owner groups in terms of votes, each of whom was offered to appoint a representative to constitute the company's Nomination Committee for the Annual General Meeting for the financial year January - December 2025. All three largest shareholders or owner groups have accepted to form the Nomination Committee together with the Chairman of the Company's Board of Directors.

**OncoZenge's Nomination Committee for the Annual General Meeting for the financial year January - December 2025 consists of:**

- Niclas Holmgren
- Karl Tobieson, appointed by Linc AB
- Andreas Özbek
- Daniel Ehrensträhle, Chairman of the Board

The Nomination Committee together represents 28.5 percent of the voting rights of all voting shares in the company as of September 30, 2025.

The Nomination Committee's task is to present proposals to the Annual General Meeting for the financial year January - December 2025 regarding the election of the Chairman of the Board and other members of the Board, Board fees and other remuneration to the Board members, as well as election and remuneration of auditors.

The Annual General Meeting for the financial year January - December 2025 will be held on May 27, 2026. Shareholders who wish to submit proposals to OncoZenge's Nomination Committee can do so by e-mail to [info@oncozenge.se](mailto:info@oncozenge.se) no later than April 10, 2026.

**BupiZenge™ - Potential to be the leading treatment for oral pain.**

### Contacts

Daniel Ehrensträhle Chairman of the Board E-mail: [daniel.ehrenstrahle@oncozenge.se](mailto:daniel.ehrenstrahle@oncozenge.se)  
Stian Kildal CEO Mobile: +46 76 115 3797 E-mail: [stian.kildal@oncozenge.se](mailto:stian.kildal@oncozenge.se)

**About**

OncoZenge AB (publ) is a clinical-stage pharmaceutical company developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options are insufficient, such as oral mucositis from cancer therapy. Its lead candidate, BupiZenge™, represents a novel formulation of bupivacaine in a lozenge form, aimed at providing rapid and sustained local pain relief without the risks associated with systemic opioids. OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ. For more information, please visit [www.oncozenge.se](http://www.oncozenge.se).

**OncoZenge AB**

Gustavslundsvägen 34, 167 51 Stockholm, Sweden

**Certified Adviser**

OncoZenge's Certified Adviser is Redeye AB.